BRAF and metastatic melanoma: ∙ In patients with unresectable or metastatic melanoma who no longer respond to other drugs (2014).∙ In combination with ipilimumab for the treatment of patients with BRAF V600 wild-type and BRAF V600 mutation-positive unresectable or metastatic melanoma (2015, 2016).